{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:08:32Z","timestamp":1790849312092,"version":"4.1.0"},"reference-count":128,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1517\/14656566.4.6.919","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T21:37:08Z","timestamp":1115242628000},"page":"919-940","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacotherapy of heparin-induced thrombocytopenia"],"prefix":"10.1517","volume":"4","author":[{"given":"William E","family":"Dager","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Services, University of California, Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"White","sequence":"additional","affiliation":[{"name":"Anticoagulation Service, UC Davis Medical Center, UC Davis School of Medicine, Sacramento CA, USA. rhwhite@ucdavis.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00124-2"},{"key":"e_1_2_1_6_1","unstructured":"\u2022Describes that termination of heparin alone will not prevent thrombosis in HIT."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1230"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1703"},{"key":"e_1_2_1_9_1","unstructured":"WARKENTIN TE GREINACHER A. Heparin-induced thrombocytopenia. edn. Dekker NY USA (2001)."},{"issue":"11","key":"e_1_2_1_10_1","first-page":"84b","article-title":"Trends in the incidence and diagnosis of herparin induced thrombocytopenia at a tertiary medical center","volume":"100","author":"FRANCIS IL","year":"2002","unstructured":"FRANCIS IL: Trends in the incidence and diagnosis of herparin induced thrombocytopenia at a tertiary medical center. Blood(2002) 100(11):84b.","journal-title":"Blood"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.3.181.30928"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30515-X"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.5858\/2002-126-1415-PCMALT"},{"key":"e_1_2_1_14_1","unstructured":"\u2022\u2022Describes the use of HIT antibody assays and includes guidelines on when platelet counts should be checked when using heparin."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.407945.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","unstructured":"JANUZZI IL Jr JANG IK: Heparin induced thrombocytopenia: diagnosis andWARKENTIN TE KELTON JG: Delayed-onset heparin-induced thrombocytopenia and thrombosis.Ann. Intern. Med. (2001) 135(7):502\u2013506. Initial description of delayed onset of HIT.","DOI":"10.7326\/0003-4819-135-7-200110020-00009"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","unstructured":"\u2022\u2022contemporary antithrombin management.20.Thromb. Thrombolysis (1999) 7(3):259\u2013264.","DOI":"10.1023\/A:1008979010033"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","unstructured":"WALENGA JM JESKE WP MESSMORE HL: Mechanisms of venousand arterial thrombosis in heparin-induced21.thrombocytopenia. j. Thromb. Thrombolysis (2000) 10\\(Suppl. 1):13\u201320.","DOI":"10.1023\/A:1027372901367"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","unstructured":"BOSHKOV LK WARKENTIN TE HAYWARD CP ANDREW M KELTON JG: Heparin-inducedthrombocytopenia and thrombosis: clinical22.and laboratory studies. Br. Haematol (1993) 84(2):322\u2013328.","DOI":"10.1111\/j.1365-2141.1993.tb03072.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","unstructured":"WARKENTIN TE ELAVATHIL LJ HAYWARD CP JOHNSTON MA RUSSETT II KELTON JG: The23.pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. (1997) 127(9):804\u2013812.24.","DOI":"10.7326\/0003-4819-127-9-199711010-00005"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104263441704"},{"key":"e_1_2_1_22_1","unstructured":"\u2022\u2022Describes the three different time sets fromheparin exposure to development of HIT."},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","unstructured":"LUBENOW N KEMPF R EICHNER A 25.EICHLER P CARLSSON LE GREINACHER A: Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest (2002) 122(1):37\u201342.","DOI":"10.1378\/chest.122.1.37"},{"key":"e_1_2_1_24_1","unstructured":"\u2022Describes early onset HIT and lack of increased risk for re-developing recurrent HIT after 3 months."},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x"},{"key":"e_1_2_1_26_1","unstructured":"WARKENTIN TE: Clinical presentation of heparin-induced thrombocytopenia.Semin. Hematol (1998) 35(4 Suppl. 5):9\u201316; Discussion 35\u201316."},{"key":"e_1_2_1_27_1","unstructured":"WARKENTIN TE SOUTAR RL PANJU AA GINSBERG IS: Acute sytemic28.reactions to intravenous bolus heparin therapy: characterization and relationships to heparin induced thrombocytopenia. Immunohematology (1997):160."},{"key":"e_1_2_1_28_1","doi-asserted-by":"crossref","unstructured":"RICE L ATTISHA WK DREXLER A FRANCIS IL: Delayed-onset heparin-induced thrombocytopenia. Ann. Intern.Med. (2002) 136 (3):210\u2013215.\u2022\u2022","DOI":"10.7326\/0003-4819-136-3-200202050-00009"},{"key":"e_1_2_1_29_1","unstructured":"\u2022Describes potential for HIT to occur up to 40 days after heparin or LMWH is29.discontinued."},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","unstructured":"\u2022\u2022GREINACHER A JANSSENS U BERG G et al: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation (1999) 100(6):587\u2013593.The second initial study using lepirudin for treatment of HIT.","DOI":"10.1161\/01.CIR.100.6.587"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90332-8"},{"issue":"2","key":"e_1_2_1_32_1","first-page":"149","article-title":"Risk factors for thrombosis in patients with immune mediated heparin induced thrombocytopenia","volume":"252","author":"FABIS F","year":"2002","unstructured":"FABIS F, LUZZATTO G, SOINI B: Risk factors for thrombosis in patients with immune mediated heparin induced thrombocytopenia. Intern. Med. (2002) 252(2):149\u2013154.","journal-title":"Intern. Med."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00258-6"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322003"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200301000-00020"},{"key":"e_1_2_1_36_1","doi-asserted-by":"crossref","unstructured":"WARKENTIN TE: Laboratory testing for heparin-induced thrombocytopenia. Thromb. Thrombolysis (2000) 10\\(Suppl. 1):35\u201345.","DOI":"10.1023\/A:1027381103184"},{"key":"e_1_2_1_37_1","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy","volume":"1229","author":"OLSON JD","year":"1998","unstructured":"OLSON JD, ARKIN CF, BRANDT IT et al.: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch. Pathol Lab. Med. (1998) 1229):782\u2013798.","journal-title":"Arch. Pathol Lab. Med."},{"key":"e_1_2_1_38_1","unstructured":"CAMPBELL KR MAHAFFEY KW LEWIS BE et al.: Bivalirudin in patients"},{"key":"e_1_2_1_39_1","unstructured":"\u2022\u2022with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J. Invasive Cardiol (2000) 12:F14\u2013F19."},{"key":"e_1_2_1_40_1","unstructured":"ORTEL TL CHONG BH: New treatment options for heparin-induced thrombocytopenia. Semin. Hematol (1998) 35(4 Suppl. 5):26\u201334 (Discussion 35\u201326)."},{"key":"e_1_2_1_41_1","first-page":"74","article-title":"danaparoid sodium) use in the syndrome of heparin-induced-thrombocytopenia","volume":"8","author":"MAGNANI HN","year":"1997","unstructured":"MAGNANI HN: Orgaran (danaparoid sodium) use in the syndrome of heparin-induced-thrombocytopenia. Platelets (1997) 8:74\u201381.","journal-title":"Platelets"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615946"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1616046"},{"issue":"6","key":"e_1_2_1_44_1","first-page":"903","article-title":"Danaparoid","volume":"54","author":"WILDE MI","year":"1997","unstructured":"WILDE MI, MARKHAM A: Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs (1997) 54(6):903\u2013924.","journal-title":"A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs"},{"key":"e_1_2_1_45_1","first-page":"A4","article-title":"Anti-hirudin antibodies induced by recombinant hirudin in the treatment of heparin-induced thrombocytopenia (HIT)","volume":"72","author":"ETCHER P","year":"1996","unstructured":"ETCHER P, GREINACHER A: Anti-hirudin antibodies induced by recombinant hirudin in the treatment of heparin-induced thrombocytopenia (HIT). Ann. Hematol (1996) 72:A4.","journal-title":"Ann. Hematol"},{"key":"e_1_2_1_46_1","unstructured":"MCKAY L: Personal communication: Berlex Laboratories (2002)."},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.1.73"},{"key":"e_1_2_1_48_1","unstructured":"\u2022\u2022Initial study on effectiveness of lepirudinin managing patients with HIT."},{"issue":"11","key":"e_1_2_1_49_1","first-page":"704a","article-title":"N,GREINACHER A: Results of the third prospective study of treatment with lepirudin in patients with heparin-induced thrombocytopenia (HIT)","volume":"100","author":"ETCHER P","year":"2002","unstructured":"ETCHER P, LUBENOW N,GREINACHER A: Results of the third prospective study of treatment with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Blood (2002) 100(11):704a.","journal-title":"Blood"},{"issue":"11","key":"e_1_2_1_50_1","first-page":"502a","article-title":"P,GREINACHER A: Results of a large drug-monitoring program confirm the safety and efficacy of lepirudin in patients with immune-mediated heparin-inducedthrombocytopenia (HIT)","volume":"100","author":"LUBENOW N","year":"2002","unstructured":"LUBENOW N, ETCHER P,GREINACHER A: Results of a large drug-monitoring program confirm the safety and efficacy of lepirudin in patients with immune-mediated heparin-inducedthrombocytopenia (HIT). Blood (2002) 100(11):502a.","journal-title":"Blood"},{"key":"e_1_2_1_51_1","unstructured":"LUBENOW N ETCHER P LIETZ T GREINACHER A: Meta-analysis of the three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. Blood (2002) 100(11):501a-502a."},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.846"},{"key":"e_1_2_1_53_1","doi-asserted-by":"crossref","unstructured":"POTZSCH B MADLENER K SEELIG C RIESS CE GREINACHER A MULLER-BERGHAUS G: Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time.Thromb. Haemost. (1997) 77(5):920\u2013925.","DOI":"10.1055\/s-0038-1656078"},{"issue":"11","key":"e_1_2_1_54_1","first-page":"130b","article-title":"The effects of lepirudin on the INR","volume":"100","author":"MATTSON JC","year":"2002","unstructured":"MATTSON JC, SMYTHE MA: The effects of lepirudin on the INR. Blood (2002) 100(11):130b.","journal-title":"Blood"},{"issue":"11","key":"e_1_2_1_55_1","first-page":"130b","article-title":"The management of protime INR effect by the direct thrombin inhibitor lepirudin in patients with heparin-induced thrombocytopenia","volume":"100","author":"NGUYEN PH","year":"2002","unstructured":"NGUYEN PH, BAKER KR, RICE L: The management of protime INR effect by the direct thrombin inhibitor lepirudin in patients with heparin-induced thrombocytopenia. Blood (2002) 100(11):130b.","journal-title":"Blood"},{"issue":"5","key":"e_1_2_1_56_1","first-page":"834","article-title":"Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial","volume":"77","author":"SCHIELE F","year":"1997","unstructured":"SCHIELE F, LINDGAERDE F, ERIKSSON H et al.: Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb. Haemost. (1997) 77(5):834\u2013838.","journal-title":"International Multicentre Hirudin Study Group. Thromb. Haemost."},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(00)00253-X"},{"key":"e_1_2_1_58_1","doi-asserted-by":"crossref","unstructured":"ERIKSSON BI WILLE-JORGENSEN P KALEBO P MOURET P ROSENCHER N BOSCH P et al.: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after totalhip replacement. N Engl. I Med. (1997) 337(19):1329\u20131335.","DOI":"10.1056\/NEJM199711063371901"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200209000-00011"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.318.34881"},{"key":"e_1_2_1_61_1","unstructured":"\u2022\u2022Describes the pharmacokinetics ofargatroban in renal or hepatic failure. That renal failure has no effect on elimination and that in hepatic failure dosing reductions need consideration."},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","unstructured":"REICHERT MG MACGREGOR DA KINCAID EH DOLINSKI SY: Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.Ann. Pharmacother. (2003) 37(5):652\u2013654.","DOI":"10.1345\/aph.1C187"},{"key":"e_1_2_1_63_1","doi-asserted-by":"crossref","unstructured":"LEWIS BE WALLIS DE BERKOWITZ SD MATTHAI WH FAREED J WALENGA JM et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.Circulation (2001) 103(14):1838\u20131843.","DOI":"10.1161\/01.CIR.103.14.1838"},{"key":"e_1_2_1_64_1","unstructured":"\u2022\u2022Initial study showing the effectiveness ofargatroban in isolated HIT and HITTS."},{"key":"e_1_2_1_65_1","doi-asserted-by":"crossref","unstructured":"LEWIS BE WALLIS DE LEYA F HURSTING MJ KELTON JG: Argatroban anticoagulant in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. (2003) an Press).","DOI":"10.1201\/9780203027363.ch16"},{"key":"e_1_2_1_66_1","unstructured":"WALENGA JM FASANELLA AR IQBAL 0 et al: Coagulation laboratory testing in patients treated with argatroban. Semin. Thromb. Hemost. (1999) 25\\(Suppl. 1):61\u201366."},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.21.2078"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615601"},{"key":"e_1_2_1_69_1","unstructured":"\u2022Describes false positive effects of argatroban on the INR. Suggests means to adjust warfarin therapy when overlapping argatroban is present."},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/45.3.409"},{"key":"e_1_2_1_71_1","first-page":"91b","article-title":"Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia","volume":"98","author":"HIATT BK","year":"2001","unstructured":"HIATT BK, MACFARLANE DE, HURSTING MJ: Transition from argatroban to warfarin in patients with heparin-induced thrombocytopenia. Blood (2001) 98:91b.","journal-title":"Blood"},{"issue":"11","key":"e_1_2_1_72_1","first-page":"280a","article-title":"S,WALENGA JM, OSAKABE M, WATANABE H: Transition of treatment with iv","volume":"100","author":"BREDDIN HK","year":"2002","unstructured":"BREDDIN HK, HARDER S,WALENGA JM, OSAKABE M, WATANABE H: Transition of treatment with iv. argatroban to phenprocoumon and acenocoumarol. Blood (2002) 100(11):280a.","journal-title":"argatroban to phenprocoumon and acenocoumarol. Blood"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A204"},{"issue":"3","key":"e_1_2_1_74_1","first-page":"171","article-title":"Pharmacological properties of hirudin and its derivatives","volume":"8","author":"MONREAL M","year":"1996","unstructured":"MONREAL M, COSTA J, SALVA P: Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Drugs Aging (1996) 8(3):171\u2013182.","journal-title":"Potential clinical advantages over heparin. Drugs Aging"},{"key":"e_1_2_1_75_1","doi-asserted-by":"crossref","unstructured":"LEFEVRE G DUVAL M GAURON S et al.: Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.Clin. Pharmacol Titer: (1997) 62(1):50\u201359.","DOI":"10.1016\/S0009-9236(97)90151-X"},{"key":"e_1_2_1_76_1","doi-asserted-by":"crossref","unstructured":"SERRUYS PW HERRMAN JP SIMON R et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl. J. Med. (1995) 333(12):757\u2013763.","DOI":"10.1056\/NEJM199509213331203"},{"key":"e_1_2_1_77_1","doi-asserted-by":"crossref","unstructured":"KONG DF TOPOL EJ BITTL JA et al.: Clinical outcomes of bivalirudin for ischemic heart disease. Circulation (1999) 100(20)2049\u20132053.","DOI":"10.1161\/01.CIR.100.20.2049"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.7.2155"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00253a020"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651573"},{"key":"e_1_2_1_81_1","doi-asserted-by":"crossref","unstructured":"KOSTER A CHEW D GRUNDEL M BAUER M KUPPE H SPIESS BD: Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth. Analg. (2003) 96 (2)383-386; Table of Contents.","DOI":"10.1213\/00000539-200302000-00015"},{"key":"e_1_2_1_82_1","doi-asserted-by":"crossref","unstructured":"BATES SM WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. I Cardiol (1998) 82(8B):12P\u201318P.","DOI":"10.1016\/S0002-9149(98)00660-2"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.7.853"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.5.2385"},{"key":"e_1_2_1_85_1","doi-asserted-by":"crossref","unstructured":"BITTL JA FEIT F: A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators.Am.j Cardiol (1998) 82(8B):43P\u201349P","DOI":"10.1016\/S0002-9149(98)00766-8"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509213331204"},{"key":"e_1_2_1_87_1","doi-asserted-by":"crossref","unstructured":"GUSTAFSSON D NYSTROM J CARLSSON S et a\/.: The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties biochemical and pharmacodynamic effects. Thromb. Res. (2001) 101(3):171\u2013181.","DOI":"10.1016\/S0049-3848(00)00399-6"},{"key":"e_1_2_1_88_1","unstructured":"SAMAMA MM WALENGA JM KAISER B FAREED J: Specific Factor Xa inhibitors. In: Cardiovascular thrombosis: thrombocardiology and thromboneurology Verstraete M Fuster V Topol EJ (Eds) Lippincott-Raven Philadelphia USA (1998):173\u2013188."},{"key":"e_1_2_1_89_1","doi-asserted-by":"crossref","unstructured":"HIRSH J: New anticoagulants. Am. Heart J. (2001) 142\\(Suppl. 2):53\u201358.","DOI":"10.1067\/mhj.2001.117078"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/107602969900500410"},{"key":"e_1_2_1_91_1","doi-asserted-by":"crossref","unstructured":"WARKENTIN TE: Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann. Intern. Med. (2001) 135(8 Pt. 1):589\u2013593.","DOI":"10.7326\/0003-4819-135-8_Part_1-200110160-00009"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10181"},{"key":"e_1_2_1_93_1","unstructured":"\u2022Describes the risk of early DTI cessation prior to therapeutic oral anticoagulation."},{"key":"e_1_2_1_94_1","unstructured":"SRINIVASAN A RICE L MURPHY S:Warfarin-induced skin necrosis and venous limb gangrene with heparin induced thrombocytopenia. Blood (2001) 98:271a.ao.WARKENTIN TE: Heparin-inducedthrombocytopenia part 2: clinical course and treatment. J. Crit. Illness (2002) 17(6):215\u2013221."},{"key":"e_1_2_1_95_1","unstructured":"WALENGA JM JESKE WP WALLIS DE et al.: Clinical experience with combined treatment of thrombin inhibitors and GPIIb\/IIIa inhibitors in patients with HIT. &min. Thromb. Hemost. (1999) 25\\(Suppl. 1):77\u201381."},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614206"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-002-1443-y"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06482.x"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.3109\/10731199109117825"},{"key":"e_1_2_1_100_1","unstructured":"KOIDE M YAMAMOTO S MATSUO M SUZUKI S ARIMA N MATSUO T: Anticoagulation for heparin-"},{"key":"e_1_2_1_101_1","doi-asserted-by":"crossref","unstructured":"\u2022\u2022induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring hemodialysis. Nephrel Dial. Transplant. (1995) 10:2137\u20132140.","DOI":"10.1093\/ndt\/10.11.2137"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656028"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35288"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.7.492.33671"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.56.s72.2.x"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10282"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.13.1123.35039"},{"key":"e_1_2_1_108_1","unstructured":"ROBS ON R: The use of bivalirudin in patients with renal impairment.Invasive Cardiel (2000) 12(Suppl. F):33F\u201336F."},{"key":"e_1_2_1_109_1","unstructured":"CHONG BH: Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Heparin-induced Thrembecytepenia. Warkentin TE Greinacher A (Eds) Marcel Dekker NY USA (2000):291\u2013311."},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35284"},{"key":"e_1_2_1_111_1","unstructured":"\u2022\u2022Reviews the available literature managingHIT in pregnancy."},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)82018-8"},{"issue":"1","key":"e_1_2_1_113_1","first-page":"67","article-title":"Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin","volume":"49","author":"HUHLE G","year":"2000","unstructured":"HUHLE G, GEBERTH M, HOFFMANN U, HEENE DL, HARENBERG J: Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.Cynecel \u00b0Enter Invest. (2000) 49(1):67\u201369.","journal-title":"Cynecel \u00b0Enter Invest"},{"key":"e_1_2_1_114_1","first-page":"87","article-title":"Treatment of a woman with a lupus syndrome and cutaneous allergy to heparin\/heparinoid by subcutaneous r-hirudin throughout pregnancy","volume":"80","author":"HARENBERG J","year":"2001","unstructured":"HARENBERG J, HOFFMANN U, LIEBE V: Treatment of a woman with a lupus syndrome and cutaneous allergy to heparin\/heparinoid by subcutaneous r-hirudin throughout pregnancy. Ann. Hematel (2001) 80:87.","journal-title":"Ann. Hematel"},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90178-Q"},{"key":"e_1_2_1_116_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.2.191"},{"key":"e_1_2_1_117_1","first-page":"606","article-title":"Successful treatment of heparin-induced thrombocytopenia (HIT) Type II in childhood with recombinant hirudin","volume":"145","author":"SCHIFFMAN H","year":"1997","unstructured":"SCHIFFMAN H, UNTERHALT M, HARMS K, FIGULLA HR, VOLPEL H, GREINACHER A: Successful treatment of heparin-induced thrombocytopenia (HIT) Type II in childhood with recombinant hirudin. Menai Kinderheilkd (1997) 145:606\u2013612.","journal-title":"Menai Kinderheilkd"},{"key":"e_1_2_1_118_1","doi-asserted-by":"crossref","unstructured":"NGUYEN TN GAL P Jr CARL OS R: Lepirudin use in a neonate with heparin-induced thrombocytopenia.Ann. Pharmacether. (2003) 37(2):229\u2013233.","DOI":"10.1177\/106002800303700214"},{"key":"e_1_2_1_119_1","doi-asserted-by":"crossref","unstructured":"RANZE 0 RANZE P MAGNANI HN GREINACHER A: Heparin-induced thrombocytopenia in paediatric patients-a review of the literature and a new case treated with danaparoid sodium. Eur. Pediatr. (1999) 158\\(Suppl. 3):5130\u20135133.","DOI":"10.1007\/PL00014338"},{"key":"e_1_2_1_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70144-1"},{"issue":"11","key":"e_1_2_1_121_1","first-page":"269a","article-title":"Pharmacokinetics of Argatroban in a 6-month old congenital cardiac patient with previously diagnosed heparin-inducedthrombocytopenia (HIT)","volume":"100","author":"BOSHKOV LK","year":"2002","unstructured":"BOSHKOV LK, THOMAS G, KIRBY A, SHEN I, SWANSON V, BURCH G et al: Pharmacokinetics of Argatroban in a 6-month old congenital cardiac patient with previously diagnosed heparin-inducedthrombocytopenia (HIT). Bleed (2002) 100(11):269a.","journal-title":"Bleed"},{"key":"e_1_2_1_122_1","doi-asserted-by":"publisher","DOI":"10.1053\/cr.2000.5861"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)01289-8"},{"key":"e_1_2_1_124_1","doi-asserted-by":"crossref","unstructured":"LIU H FLEMING NW MOORE PG: Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass.Clin. Anesth. (2002) 14 (6):452\u2013455.","DOI":"10.1016\/S0952-8180(02)00386-0"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)01329-1"},{"key":"e_1_2_1_126_1","doi-asserted-by":"crossref","unstructured":"BECKER RC: Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting. Thremb. Thrembelysis (2000) 10\\(Suppl. 1):59\u201368.","DOI":"10.1023\/A:1027385304093"},{"key":"e_1_2_1_127_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.118271"},{"key":"e_1_2_1_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)02022-1"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)00602-5"},{"key":"e_1_2_1_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)04125-5"},{"issue":"9303","key":"e_1_2_1_131_1","first-page":"294","article-title":"principal results of a meta-analysis based on individual patients' data","volume":"359","author":"Direct thrombin inhibitors in acute coronary syndromes","year":"2002","unstructured":"Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. The direct thrombin inhibitor trialists' collaborative group. Lancet (2002) 359(9303):294\u2013302.","journal-title":"The direct thrombin inhibitor trialists' collaborative group. Lancet"},{"key":"e_1_2_1_132_1","doi-asserted-by":"crossref","unstructured":"LEWIS BE MATTHAI WH COHEN M et al.: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardievasc. Intervent. (2002) 57:177-184.Affiliation","DOI":"10.1002\/ccd.10276"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.4.6.919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:04:04Z","timestamp":1772759044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.4.6.919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":128,"aliases":["10.1517\/eoph.4.6.919.22193"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1517\/14656566.4.6.919"],"URL":"https:\/\/doi.org\/10.1517\/14656566.4.6.919","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}